{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T05:03:08Z","timestamp":1780117388442,"version":"3.54.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s12325-026-03570-y","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T08:01:16Z","timestamp":1774857676000},"page":"2496-2509","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Switch Rates, Treatment Patterns, and Healthcare Costs Among Patients With Spasticity Treated With Botulinum Toxins"],"prefix":"10.1007","volume":"43","author":[{"given":"Annaliza","family":"Dominguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darshini","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivaji","family":"Manthena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"issue":"1\u20132","key":"3570_CR1","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1080\/09638280400014576","volume":"27","author":"A Pandyan","year":"2005","unstructured":"Pandyan A, Gregoric M, Barnes M, Wood D, Wijck FV, Burridge J, et al. Spasticity: clinical perceptions, neurological realities and meaningful measurement. Disabil Rehabil. 2005;27(1\u20132):2\u20136. https:\/\/doi.org\/10.1080\/09638280400014576.","journal-title":"Disabil Rehabil"},{"issue":"1","key":"3570_CR2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/14737175.2021.2021072","volume":"22","author":"J Wissel","year":"2022","unstructured":"Wissel J, Ri S. Assessment, goal setting, and botulinum neurotoxin a therapy in the management of post-stroke spastic movement disorder: updated perspectives on best practice. Expert Rev Neurother. 2022;22(1):27\u201342. https:\/\/doi.org\/10.1080\/14737175.2021.2021072.","journal-title":"Expert Rev Neurother"},{"issue":"9","key":"3570_CR3","doi-asserted-by":"publisher","first-page":"3986","DOI":"10.1007\/s12325-023-02563-5","volume":"40","author":"M Hull","year":"2023","unstructured":"Hull M, Anupindi VR, DeKoven M, He J, Bouchard J. Botulinum toxin utilization, treatment patterns, and healthcare costs among patients with spasticity or cervical dystonia in the US. Adv Ther. 2023;40(9):3986\u20134003. https:\/\/doi.org\/10.1007\/s12325-023-02563-5.","journal-title":"Adv Ther"},{"issue":"5","key":"3570_CR4","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1136\/practneurol-2011-000155","volume":"12","author":"A Kheder","year":"2012","unstructured":"Kheder A, Nair KPS. Spasticity: pathophysiology, evaluation and management. Pr Pract Neurol. 2012;12(5):289. https:\/\/doi.org\/10.1136\/practneurol-2011-000155.","journal-title":"Pr Pract Neurol"},{"issue":"8","key":"3570_CR5","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1002\/pmrj.13211","volume":"16","author":"M Verduzco-Gutierrez","year":"2024","unstructured":"Verduzco-Gutierrez M, Raghavan P, Pruente J, Moon D, List CM, Hornyak JE, et al. AAPM&R consensus guidance on spasticity assessment and management. PMR. 2024;16(8):864\u201387. https:\/\/doi.org\/10.1002\/pmrj.13211.","journal-title":"PMR"},{"issue":"19","key":"3570_CR6","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1212\/wnl.0000000000002560","volume":"86","author":"DM Simpson","year":"2016","unstructured":"Simpson DM, Hallett M, Ashman EJ, Comella CL, Green MW, Gronseth GS, et al. Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache [RETIRED]: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016;86(19):1818\u201326. https:\/\/doi.org\/10.1212\/wnl.0000000000002560.","journal-title":"Neurology"},{"key":"3570_CR7","unstructured":"BOTOX [onabotulinumtoxinA]. Package Insert. AbbVie Inc.; 2023 [cited 2026 Feb 26]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/103000s5236lbl.pdf"},{"key":"3570_CR8","unstructured":"DYSPORT [abobotulinumtoxinA]. Package Insert. Ipsen Biopharmaceuticals, Inc.; 2016 [cited 2026 Feb 26]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/125274s107lbl.pdf"},{"key":"3570_CR9","unstructured":"XEOMIN [incobotulinumtoxinA]. Package Insert. Merz Pharmaceuticals, LLC; 2018 [cited 2026 Feb 26]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/125360s073lbl.pdf"},{"issue":"11","key":"3570_CR10","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1002\/pmrj.12328","volume":"12","author":"GE Francisco","year":"2020","unstructured":"Francisco GE, Jost WH, Bavikatte G, Bandari DS, Tang SFT, Munin MC, et al. Individualized OnabotulinumtoxinA treatment for upper limb spasticity resulted in high clinician- and patient-reported satisfaction: long-term observational results from the ASPIRE study. PMR. 2020;12(11):1120\u201333. https:\/\/doi.org\/10.1002\/pmrj.12328.","journal-title":"PMR"},{"issue":"12","key":"3570_CR11","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1007\/s00702-020-02251-6","volume":"127","author":"AT Patel","year":"2020","unstructured":"Patel AT, Ward AB, Geis C, Jost WH, Liu C, Dimitrova R. Impact of early intervention with onabotulinumtoxinA treatment in adult patients with post-stroke lower limb spasticity: results from the double-blind, placebo-controlled, phase 3 REFLEX study. J Neural Transm (Vienna). 2020;127(12):1619\u201329. https:\/\/doi.org\/10.1007\/s00702-020-02251-6.","journal-title":"J Neural Transm (Vienna)"},{"issue":"1","key":"3570_CR12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jpainsymman.2016.01.007","volume":"52","author":"J Wissel","year":"2016","unstructured":"Wissel J, Ganapathy V, Ward AB, Borg J, Ertzgaard P, Herrmann C, et al. OnabotulinumtoxinA improves pain in patients with post-stroke spasticity: results from a randomized, double-blind, placebo-controlled trial. J Pain Symptom Manage. 2016;52(1):17\u201326. https:\/\/doi.org\/10.1016\/j.jpainsymman.2016.01.007.","journal-title":"J Pain Symptom Manage"},{"issue":"11","key":"3570_CR13","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1016\/j.apmr.2021.06.008","volume":"102","author":"A Esquenazi","year":"2021","unstructured":"Esquenazi A, Francisco GE, Feng W, Baricich A, Gallien P, Fanning K, et al. Real-world adherence to OnabotulinumtoxinA treatment for spasticity: insights from the ASPIRE study. Arch Phys Med Rehabil. 2021;102(11):2172-2184.e6. https:\/\/doi.org\/10.1016\/j.apmr.2021.06.008.","journal-title":"Arch Phys Med Rehabil"},{"issue":"18_supplement","key":"3570_CR14","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.98.18_supplement.1673","volume":"98","author":"D Gratie","year":"2022","unstructured":"Gratie D, Mercer DW, Lee JH, Gillard P. Real-world Botulinum Toxin Type A treatment patterns in patients with spasticity (P17-11.004). Neurology. 2022;98(18_supplement):1673. https:\/\/doi.org\/10.1212\/wnl.98.18_supplement.1673. ([Serial on the Internet]).","journal-title":"Neurology"},{"issue":"1","key":"3570_CR15","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s40120-024-00692-9","volume":"14","author":"M Hull","year":"2025","unstructured":"Hull M, Anupindi VR, He J, DeKoven M, Goldberg J, Bouchard J. Treatment patterns and healthcare costs among patients with stroke and spasticity: a 2-year longitudinal study. Neurol Ther. 2025;14(1):261\u201378. https:\/\/doi.org\/10.1007\/s40120-024-00692-9.","journal-title":"Neurol Ther"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03570-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03570-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03570-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T04:51:17Z","timestamp":1780116677000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03570-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["3570"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03570-y","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,30]]},"assertion":[{"value":"6 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Annaliza Dominguez, Ning Cheng, and Shivaji Manthena are employees of AbbVie and may hold AbbVie stock. Darshini Shah is an employee of Axsome and may hold Axsome stock.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The article does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}